Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of CKD-375 vs D387 in Healthy Volunteers
NCT03848637Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of CKD-375 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum plasma concentration of Empagliflozin, Maximum plasma concentration of Metformin and 2 more. Status: unknown.
02
Drugs
CKD-375
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03848637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848637.